Ardea Biosciences - Ardea Biosciences - Focused on development of small-molecule drugs for gout, cancer, and HIV

Development Pipeline
Development-stage programs in gout and cancer
Gout
First and next-generation URAT1 transporter inhibitors for the treatment of hyperuricemia and gout
Cancer
BAY 86-9766 (formerly known as RDEA119), a mitogen-activated ERK kinase (MEK) inhibitor for the treatment of cancer, is being developed under a global license agreement with Bayer Healthcare AG

On April 21, 2012, Ardea Biosciences, Inc. entered into an agreement and plan of merger pursuant to which AstraZeneca PLC will acquire Ardea for $32.00 per share in cash, through a reverse merger of a subsidiary of AstraZeneca with and into Ardea. Upon completion of the merger, Ardea will be a subsidiary of AstraZeneca. The total transaction value is approximately $1.26 billion. The completion of the merger is subject to various customary conditions, including the approval of the Company’s stockholders and the Company expects to complete the merger in the second or third quarter of 2012. See the Company's public filings with the Securities and Exchange Commission for more information.

Scientific Publications

Scientific publications, posters and presentations relating to Ardea Biosciences’ proprietary research programs or research collaborations with other biotechnology or pharmaceutical companies will be posted once they are available.